DelveInsight’s “Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Hodgkin’s Lymphoma, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Hodgkin’s Lymphoma Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market
Key Takeaways from the Hodgkin’s Lymphoma Market Report
- The total number of incident cases of Hodgkin lymphoma in the 7MM was maximum in the US during the forecasted period.
- Hodgkin lymphoma is rare in children younger than 5 years old. But it’s the most common cancer diagnosed in adolescent’s ages 15 to 19 years.
- In the UK, 42% of Hodgkin lymphoma cases occur in females, while 58% occur in males.
- The distribution of classical Hodgkin lymphoma subtypes is as follows: nodular sclerosis classical Hodgkin lymphoma (70%), mixed cellularity classical HL (25%), lymphocyte-rich classical Hodgkin lymphoma (5%), and lymphocyte-depleted classical HL (less than 1%). Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for about 5% of all Hodgkin lymphoma cases.
- The leading Hodgkin’s lymphoma Companies such as Merck, BeiGene, Tessa Therapeutics, Genmab, Bristol-Myers Squibb, AstraZeneca, and others.
- Promising Hodgkin’s lymphoma Therapies such as Favezelimab/Pembrolizumab, TEVIMBRA (tislelizumab), Autologous CD30 CAR-T cells, GEN3017, Gemcitabine+ Bendamustine + Nivolumab, AZD3470, Ipilimumab ± Nivolumab, and others.
Stay ahead in the Hodgkin’s Lymphoma Therapeutics Market with DelveInsight’s Strategic Report @ Hodgkin’s Lymphoma Market Outlook
Hodgkin’s Lymphoma Epidemiology Segmentation in the 7MM
- Total Incident Cases of Hodgkin Lymphoma
- Stage-specific incident cases of Hodgkin lymphoma
- Type-specific Incident cases of Hodgkin Lymphoma
- Age-specific Incident cases of Hodgkin Lymphoma
- Gender-specific Incident cases of Hodgkin Lymphoma
- Treatable cases of Hodgkin Lymphoma
Download the report to understand which factors are driving Hodgkin’s Lymphoma Epidemiology trends @ Hodgkin’s Lymphoma Prevalence
Hodgkin’s Lymphoma Marketed Drugs
- KEYTRUDA (pembrolizumab): Merck
It is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. In October 2020, the US Food and Drug Administration (FDA) approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma. It was approved under the FDA’s accelerated approval regulations, based on tumor response rate and durability of response. The approval is based on data from 210 patients in the KEYNOTE-087 trial, which showed an overall response rate (ORR) of 69 percent (95% CI: 62, 75) with KEYTRUDA (200 mg every three weeks), including a complete remission rate (CRR) of 22 percent and a partial remission rate (PRR) of 47 percent.
- OPDIVO (nivolumab): Bristol Myers Squibb
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. In May 2016, the US FDA granted accelerated approval to OPDIVO (nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL). OPDIVO was approved prior to the Prescription Drug User Fee Act (PDUFA) goal date of September 1, 2016. It also received Breakthrough Therapy Designation for the treatment of relapsed or refractory classical Hodgkin lymphoma after failure of autologous hematopoietic stem cell transplant (HSCT) and brentuximab vedotin. Additionally, OPDIVO holds Orphan Drug status for the treatment of Hodgkin lymphoma. This application was granted Priority Review and approved under the FDA’s Accelerated Approval Program.
- ADCETRIS (brentuximab vedotin): Pfizer & Takeda
It is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells. ADCETRIS has received marketing authorization by regulatory authorities in more than 70 countries for relapsed or refractory Hodgkin lymphoma and sALCL. In November 2022, the FDA approved ADCETRIS, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma. This marks the first pediatric approval for brentuximab vedotin.
Hodgkin’s Lymphoma Emerging Drugs
- TEVIMBRA (tislelizumab): BeiGene
TEVIMBRA is a monoclonal antibody that is part of a drug class targeting either the PD-1 or PD-L1, which blocks the PD-1/PD-L1 pathway. This action removes the inhibition of the immune response, potentially disrupting peripheral tolerance and leading to immune-mediated adverse reactions. In August 2024, BeinGene reported completion of Phase II clinical trial of tislelizumab in participants with relapsed or refractory classical Hodgkin lymphoma (TIRHOL). Beigene also reported in March 2024, Phase II clinical trial of tislelizumab as first-line treatment of Hodgkin lymphoma for patients age 60 years and older, expected to complete in 2028.
- Favezelimab/pembrolizumab: Merck
Favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. Merck is developing a co-formulation of favezelimab/pembrolizumab for treatment of relapsed or refractory classical Hodgkin lymphoma and conducting a Phase III trial. According to Phase I/II results presented in ASCO 2024, the ORR was 83% (n = 25; 95% CI, 65-94); 11 pts (37%) had a complete response and 14 (47%) had a partial response. Median DOR was 17.0 months (range, 2.6-30.5), and an estimated 47% of responders remained in response at 24 months. Median PFS was 19.4 months (95% CI, 9.5-28.5), and the 24-month PFS rate was 46%. With additional follow-up, favezelimab plus pembrolizumab continued to demonstrate sustained antitumor activity and manageable safety in pts with anti–PD-1–naive R/R cHL.
Hodgkin’s Lymphoma Market Outlook
Hodgkin lymphoma is a cancer that forms in the lymph nodes, causing swelling in areas such as the neck, armpit, and groin. The growth of the market is primarily driven by the increasing number of special designations granted by regulatory authorities. Additionally, factors such as higher investments in healthcare infrastructure, the rising adoption of premium-priced products like immune checkpoint inhibitors, and government efforts to raise awareness in underserved regions are also contributing to this growth. Furthermore, the expanding potential in emerging economies and the growing demand for regenerative medicine are expected to create lucrative opportunities for market expansion. Strategic collaborations among market players are also playing a significant role in fostering market growth.
Get In-Depth Knowledge on Hodgkin’s Lymphoma Market Trends and Forecasts with DelveInsight @ Hodgkin’s Lymphoma Treatment Market
Hodgkin’s Lymphoma Therapeutics Market
Hodgkin lymphoma is less common than non-Hodgkin lymphoma, typically affecting adults in two age groups: 20–39 and 65+. Over 75% of adults diagnosed with Hodgkin lymphoma are cured with standard treatments like chemotherapy and radiation. The drug ADCETRIS (brentuximab vedotin) targets CD30, a protein on Hodgkin lymphoma cells, and is approved for advanced cases. It may help older patients avoid toxic chemotherapy. Clinical trials are exploring its combination with other treatments. The drug is also approved for children and adolescents with Hodgkin lymphoma. Immune checkpoint inhibitors, such as OPDIVO (nivolumab) and KEYTRUDA (pembrolizumab) are effective for recurrent Hodgkin lymphoma and are being studied in combination with other therapies. Targeted immunotherapies, like SGN-35 (anti-CD30 antibody), show promise for both relapsed and newly diagnosed patients. Additionally, adoptive immunotherapy targeting EBV-associated antigens and biotoxins delivered to tumor-associated macrophages are being researched for more personalized treatment approaches.
Hodgkin’s Lymphoma Market Analysis
Current management of Hodgkin lymphoma typically combines chemotherapy, radiation therapy, and targeted therapies, with treatment strategies tailored to the stage and subtype of the disease. For advanced-stage cases, chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) remain standard. In relapsed or refractory disease, targeted therapies like ADCETRIS and immune checkpoint inhibitors such as KEYTRUDA and OPDIVO play a central role.
Scope of the Hodgkin’s Lymphoma Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Hodgkin’s Lymphoma Companies- Merck, BeiGene, Tessa Therapeutics, Genmab, Bristol-Myers Squibb, AstraZeneca and others.
- Hodgkin’s Lymphoma Therapies- Favezelimab/Pembrolizumab, TEVIMBRA (tislelizumab), Autologous CD30 CAR-T cells, GEN3017, Gemcitabine+ Bendamustine + Nivolumab, AZD3470, Ipilimumab ± Nivolumab, and others.
- Hodgkin’s Lymphoma Therapeutic Assessment: Hodgkin’s Lymphoma current marketed and Hodgkin’s Lymphoma emerging therapies
- Hodgkin’s Lymphoma Market Dynamics: Hodgkin’s Lymphoma market drivers and Hodgkin’s Lymphoma market barriers
- Hodgkin’s Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Hodgkin’s Lymphoma Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Hodgkin’s Lymphoma Market Report @ Hodgkin’s Lymphoma Market Drivers and Barriers
Table of Content
1 Key Insights
2 Hodgkin’s Lymphoma Market Report Introduction
3 Hodgkin’s Lymphoma Market Overview by Therapies
4 Methodology of Hodgkin’s Lymphoma Epidemiology and Market
5 Executive Summary of Hodgkin’s Lymphoma
6 Key Events
7 Disease Background and Overview: Hodgkin’s Lymphoma
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Hodgkin’s Lymphoma Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
